Press Release Archive

(BUSINESS WIRE)--Pfizer Animal Health and American Humane Association today announced a partnership to conduct a study on the impact of animal-assisted therapy on pediatric oncology patients, as well as on their parents, caregivers, siblings, and other close family members. The partnership — which includes a $282,000 grant from Pfizer and the Pfizer Foundation — exemplifies the strategic goal of both organizations to better

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the data from its two pivotal Phase 3 immunogenicity and safety trials of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in adults aged 50 years and older met all study endpoints. These studies provide the clinical foundation for the regulatory filings that have been submitted in the United States, the European Union and more than a dozen other

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from a Phase 3 12-week efficacy sub-study, which found that PRISTIQ® (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI), significantly reduced the number and severity of moderate-to-severe hot flashes in postmenopausal women. The data were presented at the 59th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in Washington

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by David Simmons, President and General Manager, Emerging Markets and Established Products, at the Bank of America Merrill Lynch 2011 Healthcare Conference on Tuesday, May 10, 2011 at 11:20 a.m. Pacific Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Bank of

(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 20-cent second-quarter 2011 dividend on the company’s common stock, payable June 7, 2011, to shareholders of record at the close of business on May 13, 2011. The second-quarter 2011 cash dividend will be the 290th consecutive quarterly dividend paid by Pfizer. “Through dividends and share repurchases, we returned approximately $7.1 billion to our shareholders in

"By drawing upon Pfizer’s innovative science core, we are now introducing the first of a series of clinically-based nutrition products that help provide the optimal nutrients for children."

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Central Daylight Time) on Thursday, April 28. To access the Webcast, visit our Web site at www.pfizer.com/annualmeeting and click on the “Annual Meeting of Shareholders Webcast” link. Information on accessing and pre-registering for the Webcast will be available at www.pfizer.com beginning

(BUSINESS WIRE)--Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study (A3921044) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor. ORAL Scan is an ongoing two-year study in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) and were randomized to receive tofacitinib 5 or 10 mg

(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. FDA Oncologic Drugs Advisory Committee (ODAC) voted 8-2 that SUTENT® (sunitinib malate) provides a favorable benefit-risk profile for the treatment of unresectable pancreatic neuroendocrine tumors (NET). The panel’s advice will be considered by the FDA when finalizing its review of Pfizer’s supplemental New Drug Application (sNDA) for sunitinib for this indication. "We